Radar · Immunotherapy in England
Best Immunotherapy Companies in England, United Kingdom
The 114 best Immunotherapy companies in England, United Kingdom in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Kymab.
By Riya SenguptaFinancials
114companies tracked
$3.3Bdisclosed funding
0unicorns
69have raised
FLIAR INTELLIGENCE · IMMUNOTHERAPY × ENGLAND
Our analysis of 50 Immunotherapy companies
$8.8b in tracked funding; 69% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
69%cloud-native stacks
2025funding peak (by rounds)
2017median founding year
42median Fliar Index™
188kcombined LinkedIn audience
41%of audience held by top 3
4companies hiring publicly (12 mo)
Ranked: Best Immunotherapy companies in England
| # | Company | Disclosed funding | Last round | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|
| 1 | Kymab Provider of monoclonal antibody therapeutics for multiple diseases | $348M | 83 mo ago | 183 | Allan Bradley Founder & Director | 872 patents Immunotherapy antibodies targeting immune checkpoints and co‑stimulatory receptors | — |
| 2 | Quell Developer of engineered regulatory T cell therapies for immune diseases | $344M | 41 mo ago | 18 | Giovanna Lombardi Co-Founder | — | 1 partnership |
| 3 | Achilles Therapeutics Developer of T-cell therapies for cancer | $242M | 47 mo ago | 118 | Charles Swanton Co-Founder | 56 patents Neoantigen discovery and peptide synthesis for personalized cancer immunotherapy | — |
| 4 | Pheon Therapeutics Developer of antibody drug conjugates for treating solid tumor cancers | $188M | 25 mo ago | 8 | Bertrand Damour CEO | 37 patents Targeted antibody‑drug conjugates and novel cytotoxic small‑molecule therapeutics. | — |
| 5 | Autolus Clinical-stage biopharmaceutical provider developing CAR T therapies for cancer and autoimmune diseases | $181M | 28 mo ago | 51 | Martin Pule Founder | 648 patents Patents concentrated in chemistry & materials | 1 award |
| 6 | Crescendo Biotechnology company developing antibody-based cancer immunotherapies and targeted biologic treatments | $141M | 34 mo ago | 43 | Theodora Harold CEO | — | — |
| 7 | Mereo BioPharma Developer of therapeutics for cancer and rare diseases | $141M | 72 mo ago | 56 56 → 45 (-20%) · sector median +46% | Charles Sermon Co-Founder | 273 patents Anti‑sclerostin antibodies for osteogenesis imperfecta and neutrophil elastase inhibitors for respiratory disease | — |
| 8 | MiroBio Developer of therapeutics for auto-immune diseases | $132M | 48 mo ago | 29 | Simon Davis Co-Founder | 69 patents Therapeutic antibodies targeting BTLA and CD200R immune checkpoint proteins. | — |
| 9 | Myricx Bio Developer of antibody drug conjugates for the treatment of cancer | $121M | 23 mo ago | 6 | Robin Carr CEO | — | — |
| 10 | Vicebio Developer of vaccines to treat viral infectious diseases 35Growth top 15%Funding top 26%News top 26%Moat top 47% All 9 signals ▾Growthtop 15% Fundingtop 26% Newstop 26% Moattop 47% Talentbottom 49% Globalbottom 37% Patentsbottom 35% Marketbottom 25% Innovationbottom 22% Growth: Fresh capital in last 24 mo Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $100M | 20 mo ago | 4 | Emmanuel Hanon CEO | 2 patents Recombinant chimeric fusion protein vaccines for hMPV and RSV respiratory viruses | — |
| 11 | NodThera Developer of therapeutics for treating inflammatory and neuroinflammatory diseases | $95M | 72 mo ago | 19 19 → 27 (+42%) · sector median +46% | Alan Watt CEO | 140 patents Synthesis of heterocyclic carbamate/urea compounds for inflammasome‑targeted drugs | — |
| 12 | Allergy Therapeutics Developer of treatments for allergy and immune related disorders | $94M | 95 mo ago | 601 601 → 380 (-37%) · sector median +46% | — | 45 patents Allergen-specific immunotherapy vaccines for food allergy treatment | — |
| 13 | Replimune Developer of oncolytic immunotherapies | $87M | 105 mo ago | 152 152 → 362 (+138%) · sector median +46% | Philip Astley-Sparke Co-Founder | 92 patents Engineered oncolytic viruses for cancer immunotherapy and targeted gene delivery | — |
| 14 | Enara Bio Developer of T-cell based cancer-cell interface for therapeutics | $84M | 20 mo ago | 38 38 → 68 (+79%) · sector median +46% | Kevin Pojasek CEO & President | 63 patents Bispecific polypeptide therapeutics targeting novel cancer antigens for immunotherapy | — |
| 15 | Cytospire Therapeutics Provider of immune cell engagers for treating cancer 53Funding top 24%Global top 45%Talent bottom 49% All 3 signals ▾Fundingtop 24% Globaltop 45% Talentbottom 49% Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) Global: Investors from 4 countries beyond United Kingdom rank vs industry peers · Fliar Intelligence Index 53/100 | $83M | 1 mo ago | — | Natalie Mount CEO | — | 1 award |
| 16 | Centauri Therapeutics Developer of immunotherapeutics to treat infectious diseases 35Funding top 26%Growth top 35%Moat top 36%Patents top 46% All 9 signals ▾Fundingtop 26% Growthtop 35% Moattop 36% Patentstop 46% Talentbottom 49% Innovationbottom 42% Globalbottom 42% Techbottom 41% Marketbottom 25% Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Growth: Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 35/100 | $65M | 3 mo ago | 6 | Jennifer Schneider CEO | 50 patents Patents concentrated in chemistry & materials | — |
| 17 | Prokarium Developer of bacterial immunotherapy treatments for various types of cancer | $62M | 41 mo ago | 20 20 → 17 (-15%) · sector median +46% | Ibraheem Mahmood CEO | 77 patents Patents concentrated in health & consumer products | — |
| 18 | T-Therapeutics Developer of T-cell-based rtherapeutics for cancer treatment 62Patents top 12%Innovation top 19%Moat top 26%News top 27% All 10 signals ▾Patentstop 12% Innovationtop 19% Moattop 26% Newstop 27% Fundingtop 30% Growthtop 32% Talenttop 38% Techbottom 47% Globalbottom 45% Marketbottom 32% Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21 rank vs industry peers · Fliar Intelligence Index 62/100 | $59M | 7 mo ago | — | Haydn Prosser Co-Founder & Director | 239 patents Therapeutic nucleic acid agents for gene expression inhibition (antisense, siRNA, oligonucleotide conjugates). | 1 job opening |
| 19 | VHsquared Designs and develops antibodies engineered to be stable in the gastrointestinal (GI) tract. | $58M | 59 mo ago | 8 | Rod Richards CEO | 62 patents Design and synthesis of therapeutic peptides and protease‑cleavable peptide drug conjugates | — |
| 20 | Ixaka Developer of cell-based therapeutic solutions for the treatment of multiple therapeutic conditions | $54M | 65 mo ago | 9 | Vicente Gonzalez Co-Founder | — | — |
| 21 | Epsilogen Developer of immunoglobulinE antibodies for the treatment of cancer | $54M | 21 mo ago | 4 | Tim Wilson CEO at Epsilogen Ltd | 19 patents Engineered therapeutic antibodies, especially IgE and hybrid formats targeting HER2 low-expression cancers | — |
| 22 | Iksuda Therapeutics Developer of antibody drug conjugates for the treatment of solid cancers | $50M | 14 mo ago | 16 | David Simpson Co-Founder & CEO | 29 patents Design and formulation of antibody‑drug conjugates and their linkers for targeted therapy. | — |
| 23 | Epitopea Developer of immunotherapeutics for the treatment of cancer | $45M | 19 mo ago | 10 | Jon Moore CEO | — | — |
| 24 | C4X Discovery Developer of optimized drug discovery and design services | $43M | 29 mo ago | 46 | — | 130 patents Small‑molecule inhibitors of MALT1, NRF2 agonists, and integrin blockers for immuno‑inflammatory therapy | — |
| 25 | SpyBiotech Developer of vaccines for bacterial infections and cancer by using proprietary protein superglue technology | $39M | 39 mo ago | 10 10 → 20 (+100%) · sector median +46% | Simon Draper Co-Founder | 29 patents Engineering adenoviral vectors and capsid-modified viral vaccines for immunization | — |
| 26 | Adaptate Biotherapeutics Developer of T-cell based immunotherapy for treating cancer | $34M | 62 mo ago | 21 | — | 4 patents Engineered antibodies targeting TCR delta variable 1 for immunotherapy | — |
| 27 | PrEP Biopharm Developing RNA based immunomodulators for the prevention of respiratory infections | $32M | 127 mo ago | 118 | — | — | — |
| 28 | Emergex Vaccines Developer T-cell Vaccines for treating viral and bacterial infections | $30M | 51 mo ago | 19 | Storme Moore-Thornicroft Co-Founder | 89 patents Peptide-based vaccines and MHC I epitope therapeutics for coronaviruses and flaviviruses | — |
| 29 | Glide Technologies Specialty company developing drug delivery products | $29M | 112 mo ago | 22 | — | — | — |
| 30 | F-star Developer of bispecific antibodies to improve the treatment of cancer | $23M | 182 mo ago | 80 | — | 6 patents Interactive educational devices and methods for teaching and learning | — |
| 31 | Tiziana Life Sciences Developer of small-molecule drugs for cancer and autoimmune diseases | $22M | 79 mo ago | 11 | — | 79 patents Patents concentrated in chemistry & materials | — |
| 32 | Treos Bio Developer of cancer vaccines and companion diagnostics | $22M | 62 mo ago | 12 12 → 16 (+33%) · sector median +46% | — | 65 patents Personalized peptide-based cancer vaccines and immunogenic peptide discovery platforms | — |
| 33 | Leucid Bio Developer of therapeutics for the treatment of cancers | $22M | 59 mo ago | 10 10 → 23 (+130%) · sector median +46% | John Maher Co-Founder | — | — |
| 34 | Immune Targeting Systems Vaccines against mutating viruses | $20M | 195 mo ago | 46 | — | 36 patents Fluorocarbon‑conjugated peptide vaccine delivery platforms for infectious and oncology antigens | — |
| 35 | Valink Therapeutics Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases | $20M | 8 mo ago | — | Irsyad Khairil Co-Founder & CTO | — | — |
| 36 | Capella Bioscience Monoclonal antibodies (mAbs) in oncology and autoimmune disease. | $18M | 101 mo ago | 3 | — | 24 patents Therapeutic antibodies targeting LIGHT, BDCA‑2, and PD‑L1 for immune modulation | — |
| 37 | Biosceptre Develops immunotherapies for oncology | $16M | 102 mo ago | 10 10 → 15 (+50%) · sector median +46% | — | 28 patents Engineering chimeric antigen receptors and cytotoxic particle therapeutics for targeted immunotherapy | — |
| 38 | Maxion Therapeutics Developer of antibody-based drugs to treat multiple diseases | $16M | 15 mo ago | 4 | Aneesh Vellatt Co-Founder & CSO | — | 1 job opening |
| 39 | OVM Therapeutic peptide vaccines for cancer | $12M | 19 mo ago | 5 | Shisong Jiang Founder & Director | — | — |
| 40 | Macrophage Pharma Developer of small molecule drugs targeting tumor-associated macrophages | $11M | 105 mo ago | 7 | — | 54 patents Immuno‑oncology cytokine therapies (IL‑12/IFN‑γ) and p38 MAPK inhibitor drug development. | — |
| 41 | DJS Antibodies Developer of antibody therapeutics for inflammatory conditions | $8M | 28 mo ago | 16 | Robert Michael CEO | 12 patents Therapeutic antibody polypeptide design and production technologies | — |
| 42 | NK:IO Developer of small molecule therapies for hematological and solid tumors | $7M | 18 mo ago | 1 | Matthew Fuchter Co-Founder | — | — |
| 43 | Scancell Biotechnology company developing immunotherapies for cancer treatment | $6M | 18 mo ago | 22 | Phil Huillier CEO | 167 patents Glycoengineered therapeutic antibodies and vaccine antigens targeting fucosylated cancer markers | 1 award |
| 44 | Athernal Bio Developer of vaccines to target and lower the risk of cancer and other age-related diseases | $5M | 8 mo ago | — | Nirupa Desai Co-Founder | — | — |
| 45 | Evariste AI-based drug discovery platform to target synthetic lethal pathways in oncology | $4M | 33 mo ago | 9 | Anna Hercot CEO | — | — |
| 46 | VacV Developer of immuno-therapeutics for cancer treatment | $3M | 42 mo ago | 6 | Peng Liu Co-Founder | — | — |
| 47 | Spirea Developer of therapeutic solutions for cancer treatments | $3M | 48 mo ago | 1 | Myriam Ouberai Founder & CEO | 25 patents Targeted antibody‑drug conjugate therapeutics for delivering cytotoxic agents to cancer cells | 1 partnership |
| 48 | BiVictriX Therapeutics Developer of bi-specific antibody-drug conjugates for the treatment of cancer | $2M | 24 mo ago | 4 | — | — | — |
| 49 | Siftr Bio Developer of antibofy drug conjugates for cancer treatment | $1M | 18 mo ago | — | Ed Tate Co-Founder | — | — |
| 50 | Bastion Therapeutics Developer of cell therapy for inflammatory disorders and autoimmune diseases | $1M | 28 mo ago | — | Nia Emami Co-Founder & CSO | — | — |
Top 12 Immunotherapy companies in England
#1
Series A · London, England · founded 2023$83Mraised▾
Series A · London, England · founded 2023
Provider of immune cell engagers for treating cancer. It offers a portfolio of differentiated multispecific engager antibodies to enhance and direct the activity of innate and adaptive effector immune cells to discriminate between target diseased vs healthy cell for the treatment of solid tumors and other cancer.
Fliar Intelligence Index™ 53how this company ranks against its industry peers
Funding
top 24%Global
top 45%Talent
bottom 49%Funding: Raised $83.0M across 1 rounds · 1 rounds over 1 yrs (1.0/yr) · Last round Series A (May 2026)
Global: Investors from 4 countries beyond United Kingdom
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 2k LinkedIn followers
Activity (LinkedIn): 2 awards announced in 12 mo
Funding rounds
- May 2026Series A$83M
- Seed—
Founders & team
Investors
4Bio Capital, Servier, British Business Bank, Sound Bioventures, Criteria Bio Ventures, Abingworth
#2
Series A · Kent, England · founded 2014 · 6 employees$64.9Mraised▾
Series A · Kent, England · founded 2014 · 6 employees
Developer of immunotherapeutics to treat infectious diseases. The company has proprietary Alphamer technology based on "programmable immunity" in which chemically synthesised molecules redirect naturally occurring antibodies to selected pathogens to fight the infections.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Growth
top 35%Moat
top 36%Patents
top 46%Talent
bottom 49%Innovation
bottom 42%Funding: Raised $64.9M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Series A (Feb 2026)
Growth: Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 4/10 · IP moat: 50 patents · Soonicorn
Audience (LinkedIn): 3k LinkedIn followers
Funding rounds
- Feb 2026Series A$8.1M
- Jul 2025Grant (prize money)$5.1M
- Nov 2024Grant (prize money)$1.3M
- Jul 2023Series A$11.5M
Founders & team
Investors
Kent County Council, EJ Capital, Wren Capital, Discovery Park, Renaissance Capital Partners, Animatrix Capital Llp
Tech stack
CookiebotGodaddyGoogle AnalyticsHstsJqueryMicrosoft 365
#3
Series A · Cambridge, England · founded 2022$59.4Mraised▾
Series A · Cambridge, England · founded 2022
Developer of T-cell-based rtherapeutics for cancer treatment. It offers T-cell receptor-based drugs that recognise specific cancers and patient’s own T cells to kill the cancer cells and eradicate the tumour.
Fliar Intelligence Index™ 62how this company ranks against its industry peers
Patents
top 12%Innovation
top 19%Moat
top 26%News
top 27%Funding
top 30%Growth
top 32%Patents: 239 patents matched (strict assignee match) · 105 filings since 2022 vs 14 in 2017-21 · Latest publication 2026
Innovation: 239 patents (top 11% of patent-holders) · 105 filings since 2022 vs 14 in 2017-21
Moat: Editorial + unicorn rating 8/10 · IP moat: 239 patents · Soonicorn
Audience (LinkedIn): 7k LinkedIn followers — 4.0% of this cohort's audience
Hiring (LinkedIn): 4 hiring posts in 12 mo (public) · momentum -2 · hiring: Senior Scientist - Analytical Development, Protein Sciences, Research Associate - Protein Sciences
Funding rounds
- Nov 2025Series A$32M
- Nov 2023Series A$59.4M
Founders & team
Investors
Sanofi Ventures, University of Cambridge, Sofinnova Partners, F-Prime Capital, Digitalis Ventures, Cambridge Innovation Capital
Tech stack
Animate.CssAnime.JsExactmetricsFancyboxGodaddyGoogle Analytics
#4
Seed · London, England · founded 2020$19.6Mraised▾
Seed · London, England · founded 2020
Developer of bispecific antibody-drug conjugate therapeutics for oncology and other diseases. The company focuses on creating more effective drugs that differentiate between diseased and healthy cells. It utilizes a discovery engine built on synthetic protein biology, high-throughput functional screening, and artificial intelligence. The company is advancing oncology-focused programs.
Funding rounds
- Oct 2025Seed$11.8M
- Nov 2023Seed$7.8M
Founders & team
Investors
Redalpine, LongeVC, Oxford Science Enterprises, RV Invest, p53, Hoxton Ventures
Tech stack
Apple Icloud MailCloudflareHstsHttp/3JqueryJsdelivr
#5
Series A · Newcastle Upon Tyne, England · founded 2012 · 16 employees$49.6Mraised▾
Series A · Newcastle Upon Tyne, England · founded 2012 · 16 employees
Developer of antibody-drug conjugates for the treatment of solid cancers including ovarian, lung, pancreas, cervix, and renal cell carcinoma. The company's product pipeline includes IKS01 which is in pre-clinical trials, IKS02, IKS03, IKS04 which are in the discovery phase.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.5% of this cohort's audience
Funding rounds
- Mar 2025Series A$15M
- Jun 2021Series A$47M
- Jun 2012Seed$2.6M
Founders & team
Investors
Mirae Asset Capital Markets, Celltrion, Premier Partners, IP Group, North East Technology Fund, LigaChemBio
Tech stack
AzureCloudflareCloudflare Browser InsightsCookiebotGoogle AnalyticsGoogle Tag Manager
#6
Series B · Oxford, England · founded 2016 · 38 employees$84.1Mraised▾
Series B · Oxford, England · founded 2016 · 38 employees
Enara Bio is developing a T-cell based cancer-cell interface for therapeutics. The company is involved in the immune interface for cancer biology to develop and characterize immunotherapy targets, like dark antigens derived from the genomic dark matter or antigens presented by the cancer-specific MR1 receptor. The company offers proprietary TCR-directed T-cell therapies to target tumor homogeneity and cancer vaccines to generate polyclonal autologous ex vivo stimulation of T-cell products.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 9k LinkedIn followers — 4.8% of this cohort's audience
Funding rounds
- Oct 2024Series B$32.5M
- May 2021Series A$16.3M
- Nov 2019Series A$17.5M
- Apr 2018Seed$7.8M
Founders & team
Investors
M Ventures, Pfizer Ventures, Crick, RA Capital Management, Samsara BioCapital, SV Health Investors
Tech stack
Craft CmsDocusignGodaddyGoogle AnalyticsNginxOpen Graph
#7
Acquired · London, England · founded 2019 · 4 employees$100Mraised▾
Acquired · London, England · founded 2019 · 4 employees
Developer of vaccines to treat viral infectious diseases. The company has Molecular Clamp technology for high yield production of viral fusion proteins in native trimeric “prefusion” form. The lead candidate of the company includes VXB-211 which targets respiratory syncytial virus (RSV). The company has developed a pipeline for Metapneumovirus, influenza, and SARS-CoV-2.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Growth
top 15%Funding
top 26%News
top 26%Moat
top 47%Talent
bottom 49%Global
bottom 37%Growth: Fresh capital in last 24 mo
Funding: Raised $100M across 1 rounds · 1 rounds over 2 yrs (0.5/yr) · Last round Series B (Sep 2024)
News: 6 BI events in 12 mo (of 7 tracked, 2 types) · +500% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Funding rounds
- Sep 2024Series B$100M
Founders & team
Investors
TCG Crossover, Avoro Capital, VenBio, UniQuest, Medicxi
#8
Series A · London, England · founded 2019 · 6 employees$120.6Mraised▾
Series A · London, England · founded 2019 · 6 employees
Developer of antibody drug conjugates for the treatment of cancer. The company focuses on the development of a pipeline of proprietary differentiated antibody drug conjugates based on novel N-myristoyltransferase inhibitor (NMTi) payload chemistry platform to address serious unmet needs in oncology.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 7k LinkedIn followers — 3.6% of this cohort's audience
Funding rounds
- Jul 2024Series A$114M
- Oct 2019Seed$6.6M
Founders & team
Investors
Sofinnova Partners, Brandon Capital, British Patient Capital, Novo Holdings, Abingworth, Cancer Research Horizons
#9
Series B · London, England · founded 2016 · 4 employees$53.8Mraised▾
Series B · London, England · founded 2016 · 4 employees
Developer of immunoglobulin antibodies for the treatment of cancer. It offers antibodies that help in the treatment of solid tumors. The lead product candidate, MOv18 IgE is for folate receptor alpha positive cancer patients. Other products include EPS 201 for breast cancer and gastric problems.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 4k LinkedIn followers — 2.0% of this cohort's audience
Funding rounds
- Sep 2024Series B$16.4M
- Mar 2022Series B$41.1M
- Oct 2020Grant (prize money)—
- Jul 2020Grant (prize money)$627.7K
Founders & team
Investors
British Patient Capital, Novartis Venture Fund, Epidarex Capital, 3B Future Health Fund, ALSA Ventures, Gov
Tech stack
CdnjsCloudflareCloudwaysFormidable FormGoogle Font ApiGsap
#10
Series A · Babraham, England · founded 2024$4.7Mraised▾
Series A · Babraham, England · founded 2024
Developer of vaccines to target and lower the risk of cancer and other age-related diseases. The company is developing immunotherapies for high-risk clonal haematopoiesis addressing blood cancer precursor condition with the aim of stopping cancer before it starts through early and proactive therapeutic intervention.
Funding rounds
- Oct 2025Series A$4.7M
Founders & team
Investors
Delin Ventures
Tech stack
Framer SitesGodaddyGoogle Font ApiHstsHttp/3Lottiefiles
#11
Seed · Cambridge, England · founded 2021 · 10 employees$44.6Mraised▾
Seed · Cambridge, England · founded 2021 · 10 employees
Developer of immunotherapeutics for the treatment of cancer. The company's proprietary technology provides an approach to identify tumor-specific antigens, known as Cryptigens to create transformational immunotherapies including therapeutic vaccines, cell therapies, and TCR-based biologics that target broad cancer patient populations in both solid and hematological cancers.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 5k LinkedIn followers — 2.6% of this cohort's audience
Funding rounds
- Oct 2024Seed$31M
- Sep 2024Grant (prize money)$658K
- Apr 2022Seed$13.6M
Founders & team
Investors
Invest Quebec, adMare BioInnovations, Advent Life Sciences, CTI Life Sciences Fund, Cambridge Innovation Capital, Fonds de solidarite FTQ
Tech stack
CivicthemeGoogle AnalyticsGoogle Font ApiHstsIsotopeJquery
#12
Series A · Cambridge, England · founded 2020 · 4 employees$16Mraised▾
Series A · Cambridge, England · founded 2020 · 4 employees
Developer of antibody-based drugs to treat multiple diseases. The company leverages a proprietary KnotBody technology that combines the power of Knottin evolution in targeting ion channels and GPCRs with state-of-the-art antibody engineering techniques to address autoimmunity, chronic pain, and cardiovascular diseases.
LinkedIn Pulse recent public activity · Jul 2026
Audience: 8k LinkedIn followers — 4.3% of this cohort's audience
Hiring: 1 hiring post in 12 mo (public) · hiring: Program Manager – Discovery
Funding rounds
- Mar 2025Series A$72M
- Apr 2023Grant (prize money)$2.5M
- Feb 2023Series A$16M
Founders & team
Investors
Gov, Monograph, BGF, LifeArc Ventures, General Catalyst, British Patient Capital
Funding & investor landscape
$3.3Btotal disclosed funding
67companies funded
231disclosed rounds
1rounds last 90 days
Most active investors
Gov9 rounds
British Patient Capital4 rounds
Notable founders
Natalie Mount
CEO · Cytospire Therapeutics
Jennifer Schneider
CEO · Centauri Therapeutics
Haydn Prosser
Co-Founder & Director · T-Therapeutics
Allan Bradley
Co-Founder & CEO · T-Therapeutics
Irsyad Khairil
Co-Founder & CTO · Valink Therapeutics
Arne Scheu
Co-Founder & CEO · Valink Therapeutics
David Simpson
Co-Founder & CEO · Iksuda Therapeutics
Kevin Pojasek
CEO & President · Enara Bio
Houman Ashrafian
· Enara Bio
Emmanuel Hanon
CEO · Vicebio
Robin Carr
CEO · Myricx Bio
Tim Wilson
CEO at Epsilogen Ltd · Epsilogen
Prism market signals · United Kingdom · country-scoped Prism corpus, 1,681,538 docs
Market landscape — 10 sub-themes by coverage
Share of Immunotherapy coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
RESEARCH FROM England · institutions
What England researches in immunology
University of New England, NHS England, and New England Biolabs lead England's immunology research, focusing optimistically on cancer immunotherapy, CAR-T therapy, and biomarkers, with recent post-2020 momentum.
15 papersstance +0.4429% breakthrough21% concern
local research themes
Cancer Immunotherapy and BiomarkersStreptococcal Infections and TreatmentsCAR-T cell therapy researchInflammasome and immune disordersAllergic Rhinitis and SensitizationAntimicrobial Resistance in Staphylococcus
top institutions
- University of New England4
- NHS England2
- New England Biolabs2
- Public Health England1
- New England Cancer Specialists1
Common questions
How many Immunotherapy companies are there in England, United Kingdom?
Radar tracks 114 indexable Immunotherapy companies headquartered in England, United Kingdom that meet our profile-completeness bar.
What is the total funding raised by Immunotherapy companies in England, United Kingdom?
The Immunotherapy companies in England, United Kingdom on this list have raised a combined $3.3B in disclosed equity funding across 67 funded companies.
Which is the highest-funded Immunotherapy company in England, United Kingdom?
Kymab is the highest-funded Immunotherapy company in England, United Kingdom, with $348M in disclosed equity funding.
How many Immunotherapy companies in England, United Kingdom are funded?
67 of the 114 Immunotherapy companies in England, United Kingdom on this list have disclosed at least one equity funding round.
How many Immunotherapy unicorns are there in England, United Kingdom?
None of the Immunotherapy companies in England, United Kingdom on this list currently has a disclosed valuation of $1B or more.
Who are the top investors in England, United Kingdom Immunotherapy companies?
The most active investors in England, United Kingdom Immunotherapy companies on this list include Gov, IP Group, Ukri, Medicxi, Oxford Science Enterprises.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.